The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
Curated pathway from expert analysis
flowchart TD
A["Cell-Autonomous vs Non-Cell-Autonomous<br/>FUS Neuromuscular Denervation Mechanism"]
B["Perturbation-First Validation<br/>Compartment-Specific FUS Targeting"]
C["Motor Neuron Intrinsic vs Glial Contribution<br/>Conditional KO and Chimera Models"]
D["NMJ Stability Assessment<br/>Synaptic Integrity Readout"]
E["Mechanism Resolution<br/>Dominant Compartment Identification"]
F["ALS Therapeutic Strategy<br/>Compartment-Matched Intervention Design"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for ALS yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ALS.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.